Guided Therapeutics (Guided Therapeutics) Risk Assessment

View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Guided Therapeutics is: No Data: Cannot be evaluated.

Competitive Comparison of Guided Therapeutics's Risk Assessment

For the Medical Devices subindustry, Guided Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guided Therapeutics's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Risk Assessment falls into.

Guided Therapeutics (OTCPK:GTHP) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Guided Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Guided Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Guided Therapeutics (Guided Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092

Website

https://www.guidedinc.com

Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.

Executives

John E Imhoff	director, 10 percent owner	P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic	director	349 FORBES AVE, SAN RAFAEL CA 94901
Michael C James	director	2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Richard P. Blumberg	director	2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff	10 percent owner	2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright	officer: Chief Executive Officer	4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp.	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock	director	5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff	director	C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen	director	P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot	officer: VP of R & D	4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071

Guided Therapeutics (Guided Therapeutics) Headlines

From GuruFocus

Dr. Gene Cartwright, CEO of Guided Therapeutics Joins Everett Jolly on Uptick Newswire's “Stock Day” Podcast to Discuss LuViva® Advanced Cervical Scan

By Marketwired Marketwired • 05-16-2018